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Photodynamic therapy (PDT) using 5-aminolaevulinic acid (ALA) to drive production of an intracellular photosensitiser,
protoporphyrin IX (PpIX), is a promising cancer treatment. However, ALA-PDT is still suboptimal for thick or refractory tumours.
Searching for new approaches, we tested a known inducer of cellular differentiation, methotrexate (MTX), in combination with ALA-
PDT in LNCaP cells. Methotrexate alone promoted growth arrest, differentiation, and apoptosis. Methotrexate pretreatment
(1mgl
 1, 72h) followed by ALA (0.3mM, 4h) resulted in a three-fold increase in intracellular PpIX, by biochemical and confocal
analyses. After exposure to 512nm light, killing was significantly enhanced in MTX-preconditioned cells. The reverse order of
treatments, ALA-PDT followed by MTX, yielded no enhancement. Methotrexate caused a similar relative increase in PpIX, whether
cells were incubated with ALA, methyl-ALA, or hexyl-ALA, arguing against a major effect upon ALA transport. Searching for an effect
among porphyrin synthetic enzymes, we found that coproporphyrinogen oxidase (CPO) was increased three-fold by MTX at the
mRNA and protein levels. Transfection of LNCaP cells with a CPO-expressing vector stimulated the accumulation of PpIX. Our data
suggest that MTX, when used to modulate intracellular production of endogenous PpIX, may provide a new combination PDT
approach for certain cancers.
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Photodynamic therapy (PDT) using 5-aminolaevulinic acid (ALA)
as a prodrug that is converted to an intracellular photosensitiser,
protoporphyrin IX (PpIX), represents an increasingly accepted
treatment for superficial epithelial neoplasias (Kennedy et al, 1990;
Marmur et al, 2004) and for diagnostic imaging of internal
malignancies at locations where light can be delivered through an
optical fibre (Kennedy et al, 1996; Eker et al, 1999; Landry et al,
2003; Schmidbauer et al, 2004). However, ALA-mediated PDT
(ALA-PDT) remains suboptimal for the treatment of deeper
tumours, such as nodular basal cell and squamous cell carcinoma
of the skin, because recurrence rates after single treatments are
unacceptably high as compared to the current standard of care,
surgical excision (Marmur et al, 2004). For internal malignancies
in organs such as the bladder, GU tract, and oesophagus, ALA-PDT
has been used for palliative treatment of these cancers (Kennedy
et al, 1996; Waidelich et al, 2001; Friesen et al, 2002). However,
ALA-PDT in its current form seldom achieves a definitive cure of
deep or refractory tumours in any location. Clearly, new
approaches are needed, including ways to increase the clinical
responsiveness of tumour cells to ALA-PDT.
Methotrexate (MTX) is a widely used and highly successful
anticancer agent. A structural analogue of folic acid and a potent
inhibitor of dihydrofolate reductase, MTX interferes with the
synthesis of thymidylate and purine nucleotides (Hatse et al, 1999),
and blocks DNA synthesis, thereby inhibiting tumour growth.
However, another important property of MTX is its ability to
trigger cellular differentiation in a number of tumour cells,
including human and rat choriocarcinoma cells (Friedman and
Skehan, 1979; Hatse et al, 1998), human promyelocytic HL-60 cells
(Bodner et al, 1981), human neuroblastoma LA-N-1 cells (Ross
et al, 1995), as well as normal human keratinocytes (Schwartz et al,
1992). This differentiation-promoting property of MTX is of
particular interest to us. Malignant cells typically display an
uncoupling of the balance between cellular proliferation and
differentiation, in which cellular proliferation is favoured owing
to a block in maturation (Marks and Rifkind, 1991). However,
in certain cases, differentiation-inducing agents can reactivate
a tumour cell’s differentiation programme and bypass this
defective growth regulation, forcing cells into a more differentiated
state that has a more favourable clinical prognosis. One major
clinical example of this is the use of all-trans retinoic acid
for differentiation therapy of acute promyelocytic leukaemia
(Douer, 2000). Another well-known example is the successful
treatment of highly aggressive human choriocarcinoma tumours
using MTX, which was shown to induce cytodifferentiation
in human and rat choriocarcinoma cells in culture (Berkowitz
et al, 1986).
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sBecause MTX can induce cellular differentiation in some types
of tumour cells, and because we have recently shown that agents
capable of inducing cellular differentiation will also cause an
elevation in the level of PpIX photosensitiser in epithelial cells
of the skin (Ortel et al, 1998) and prostate (Ortel et al, 2002), we
became interested in the notion of combination therapy involving
MTX and ALA-PDT. Specifically, we reasoned that if MTX could
promote differentiation and PpIX accumulation in carcinoma cells,
then MTX might serve as a means to augment the efficacy of ALA-
PDT for tumour cell killing. The data described in this paper,
obtained using a carcinoma cell line, suggest that MTX may indeed
be a useful adjunct to ALA-PDT when administered before the
phototherapy.
MATERIALS AND METHODS
Source of reagents
ALA and MTX were from Sigma-Aldrich (St Louis, MO, USA).
Methyl-ALA and hexyl-ALA were obtained from ORGANIX
(Department of Biological Sciences, University of Essex, Wivenhoe
Park, Colchester, UK). R1881 was obtained from Perkin-Elmer Life
Sciences (Boston, MA, USA).
Culture of LNCaP cells
LNCaP human prostate carcinoma cells were obtained from
American Type Culture Collection (ATCC; Manassas, VA, USA)
and cultured at 371C in a humidified CO2 incubator in Rosewell
Park Memorial Institute (RPMI) 1640 medium with L-glutamine
(Mediatech Inc., Herndon, VA, USA) supplemented with 10%
foetal bovine serum (Invitrogen Corp., Carlsbad, CA, USA) and 1%
penicillin–streptomycin and 10mM HEPES buffer. To maintain
reproducible behaviour of the LNCaP cells, we found it important
to keep the cells subconfluent. The original vial of cells was thawed
and plated in the medium in a 100mm dish, and at 24h, the
medium was replaced and left on for another 3–4 days. When
nearly confluent, the cells were released with 0.25% trypsin (noting
under the microscope when cells had just detached, usually
o3min), and were replated in RPMI medium at a 1:3 dilution.
Subsequently, cells were passaged at 1:3 dilution every 3–4 days,
always before they reached full confluence.
Measurement of proliferation, differentiation and
apoptosis
Control LNCaP cells were plated in 35mm dishes at an initial
density of B100000cellsdish
 1, and after 72h of growth, were
trypsin-released and counted. Methotrexate-treated dishes were
plated at a higher initial density of B250000cellsdish
 1, to give a
final cell density that was roughly equal to the controls after 72h.
Proliferation was estimated as the ratio (percentage) of the final
trypsinised cell number divided by the number of cells plated.
Growth arrest was assessed by upregulation of p27/kip-1, and
differentiation by upregulation of E-cadherin in MTX-treated
LNCaP cells, as described (Ortel et al, 2002).
Apoptosis was measured by a fluorescein isothiocyanate (FITC)-
annexin V/propidum iodide assay (Vybrant Apoptosis Assay,
Molecular Probes Inc., Eugene, OR, USA). Supernatants from each
culture dish were collected in 15ml Falcon tubes, cells were
trypsin-released (0.5ml of trypsin) and pooled with the respective
supernatant, and cells pelleted for 10min at 1000r.p.m. in a
refrigerated centrifuge (201C). The supernatant was discarded, the
cell pellet was washed by gentle resuspension in phosphate-
buffered saline, repelleted, and the cell pellet was resuspended in
100ml of 1:5 diluted buffer supplied in the kit. In a fresh
microcentrifuge tube, 20ml of the cell suspension was mixed with
80ml of 1:5 diluted buffer, then 5ml of annexin-FITC and 1mlo f
1:10 diluted propidium iodide (supplied in the kit) was added in
each tube. After 15min at room temperature, 400ml of 1:5 diluted
buffer was added and the cell suspension was transferred to
a fluorescent-activated cell sorting (FACS) tube on ice (Becton
Dickinson Labware, Bedford, MA, USA) and measured by fluore-
scent-activated cell analysis (FACSCalibur, Becton Dickinson, CA,
USA).
Pretreatment of cells with MTX or R1881, and
measurement of PpIX in cell lysates
In all cases, cells were plated at B80–100k for untreated dishes
and B180–250k for MTX-treated dishes, in order to yield an
approximately equal cell density at the end of the experiment.
Methotrexate (1mgl
 1 in media) was added on the second day
after plating and incubated for an additional 72h, after which the
medium was aspirated and ALA in fresh medium was added. In the
experiment shown in Figure 3A, the androgen analogue R1881
(0.1mM) was added for 72h to some of the dishes. For the last 4h of
all experiments, ALA (at 0.3mM concentration, unless otherwise
noted) was added to the culture medium, the cells trypsin-released,
and final cell counts were determined with a haemocytometer. The
cells were lysed and vortexed in 2ml of 1% sodium dodecyl
sulphate in 0.1 N NaOH. The amount of PpIX per cell was
determined as follows. An aliquot of cell lysate was measured in a
scanning spectrophotometer (Horiba Instruments SA Inc., Jobin
Yvon/Spex Division, Edison, NJ, USA) and the peak area between
580 and 720nm was determined. The PpIX concentration of each
sample was calculated by comparison to a calibration curve
constructed from measuring PpIX standards, run on the same
day. Based upon the known volume of the lysate and the cell
count before lysis, the PpIX concentration was converted to total
PpIX (in pmol) per 1 million cells.
Fluorescence analysis of PpIX in living cells
Protoporphyrin IX-specific fluorescence in living LNCaP cells
was analysed by fluorescence microscopy on a confocal laser-
scanning microscope (Leica Microscopy Systems GmbH, Wetzlar,
Germany). LNCaP cells were plated on microscope coverslips
in 35mm dishes at 50000cellsdish
 1, then 24h later the culture
media were replaced either with media alone or with media
containing MTX (1mgl
 1). The cells were cultured for an
additional 72h, then ALA (0.3mM) was added to the wells for a
final 4h of incubation. Protoporphyrin IX-specific fluorescence in
the living cells was analysed on the confocal microscope. Using
excitation at 488nm, images were collected in the red channel,
through a 590nm long-pass filter.
Transient transfection of LNCaP cells for analysis of PpIX
fluorescence
LNCaP cells (3 10
5cellsdish
 1) were plated on a 22 22mm, No.
1 cover glass in a 35mm dish. At 24h, cells were transfected with
variable quantities of pcDNA3.1( ) mouse coproporphyrinogen
oxidase (CPO) expression plasmid (gift of Dr Shigeru Taketani
(Kohno et al, 1993)) using FuGENE 6 transfection reagent (Roche
Diagnostics, Indianapolis, IN, USA), exactly as described by the
manufacturer. At 24h post-transfection, the medium was replaced
with fresh medium containing 1mM ALA and incubated for 4h
before analysis of PpIX fluorescence by confocal microscopy.
Controls for the analysis included dishes with no treatment,
FuGENE only, and ALA only. Fluorescence images along with their
corresponding phase-contrast images were captured from regions
representing monolayered (not clustered) cells, using a digital
camera. Protoporphyrin IX-positive cells were counted from
fluorescence images using Adobe Photoshop software, by setting
the brightness to a fixed value that rendered approximately half
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brightness threshold was then applied to all images and kept
constant throughout the analysis. Cells above the threshold were
counted for each slide and expressed as the relative number of
PpIX-positive cells (% of total cells).
Cell survival assays
For experiments to measure the effects of MTX upon phototoxicity,
sets of 35mm dishes were plated at a cell number of 8 10
4
(control) or 2 10
5 (MTX treatment), and incubated for 24h. Then,
the control or MTX plates received fresh medium alone, or MTX in
the medium, respectively. This procedure assured similar cell
densities for both sets of cells at the time of photosensitisation,
which was confirmed by actual cell counts in parallel dishes. After
72h in MTX, cells were incubated with 0.3mM ALA (for most
experiments, unless otherwise noted) for 4h, and then exposed to
graduated doses of light delivered by a 514nm argon laser
(Coherent Inc., Santa Clara, CA, USA) for the clonogenic
experiments. Dosimetry was performed using a Coherent Laser-
mate power meter (Coherent Inc., Santa Clara, CA, USA).
For quantifying short-term phototoxicity, 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) conver-
sion to formazan at 24h was monitored by absorbance at 560nm
as described earlier (Ortel et al, 1998). This assay has been shown
to correlate well with other established measures of cytotoxicity
such as colony formation (Iinuma et al, 1994).
For quantifying long-term survival, a colony formation assay
was used. After performing ALA incubation and light exposures as
detailed above, LNCaP cells were detached using trypsin/ethylene-
diaminetetraacetic acid and resuspended in complete medium.
Serially diluted suspensions of the photosensitised cells (range
1:5–1:1375) were plated on 100mm dishes and incubated for 13
days. Cells were fixed with 0.2% buffered formalin in methanol and
stained with 0.1% aqueous crystal violet. Colonies of more than 50
cells were counted under a dissecting microscope.
To assess if the order of MTX and ALA-PDT is important for
efficacy of the combined therapy, colony formation was measured
in experiments using a reverse order of administration, that is,
ALA-PDT given first, followed by MTX treatment. Cells were
exposed for 4h to ALA (0.3mM) and irradiated with graduated
light doses. Duplicate sets of diluted samples (see above) were then
plated on 100mm dishes in medium either with or without MTX.
After 72h, the medium was replaced by fresh medium in all dishes.
After incubation for an additional 10 days, colonies were stained
and counted as described above.
RT–PCR analyses
To detect semiquantitative changes in the level of mRNAs for CPO,
PPO, FC, and PBGD in LNCaP cells, the following oligonucleotide
(oligo) pairs were used. Coproporphyrinogen oxidase: sense, 50-CG
CAGAAAAGTTCTGAAGAC-30; CPO: antisense, 50-CCATCGGGCA
GTTAGAGGTA-30;P P O :s e n s e ,5 0-CTGGGAGGTTCCTGGTTACA-30;
PPO: antisense, 50-CAACCTGTGAGCAGTCAGGA-30; FC: sense, 50-
GATGAATTGTCCCCCAACAC-30; FC: antisense, 50-GCTTCCGTCCC
ACTTGATTA-30; and PBGD: sense, 50-AAGAGTGTGGTGGGAACC
AG-30 and PBGD: antisense, 50-CATTTCTCAGGGTGCAGGAT-30.
Two micrograms of RNA, extracted from cells using Trizol reagent
(Invitrogen) exactly as described by the manufacturer, were used
for first-strand synthesis, and the following three different oligos
were tried: oligo(dT)20 (50mM); random 9-mer primers (14mM);
and individual gene-specific primers (antisense oligos for the three
genes mentioned above, 4mM each). The primers were employed in
reactions with SuperScript III H-reverse transcriptase (Invitrogen),
exactly as described by the manufacturer. Antisense G3PDH oligo
(BD Biosciences, Palo Alto, CA, USA) was used as internal control
for gene-specific first-strand synthesis. For polymerase chain
reaction (PCR) amplification, cycle conditions were as follows:
941C 2min, 941C4 5 s ,6 5 1C4 5 s ,7 2 1C 1min 25–35 cycles, and
721C 10min. G3PDH control amplimer set was used as internal
control for all three different reverse transcription–polymerase
chain reactions (RT–PCRs). Amplification products were analysed
on a 1.5% agarose gel along with molecular size markers.
A murine CPO cDNA sequence (Kohno et al, 1993) was
amplified with specific PCR primers and cloned into the TA-
cloning vector PCRII-TOPO, then transferred via restriction
enzymes SpeI/XhoI followed by ligation into the NheI/XhoI sites
of pcDNA3.1( ), both vectors were from Invitrogen Inc. This
mCPO construct was used as a standard for the RT–PCR analyses.
Epitope-targeted antibody for CPO
A rabbit polyclonal antiserum against CPO was generated from a
peptide comprising the last 12 amino acids (LEVLRHPKDWVH) of
murine CPO, as per the sequence reported by Kohno et al (1993).
This peptide has 83% homology between mouse and human at the
amino-acid level. The peptide was synthesised with an extra N-
terminal cysteine for conjugation to Keyhole limpet antigen in the
Biopolymers Core facility of the Massachusetts General Hospital,
and sent to HTI Bio-Products Inc. (Ramona, CA, USA) for rabbit
immunisation, blood collection, and affinity purification of the
antiserum. Specificity was confirmed by Western blots of
recombinant mCPO protein expressed in a pcDNA3.1( ) vector
transfected into cos-7 cells (see Figure 7C).
Western blot analyses
Cells were lysed in lysis buffer (7 M urea, 2% IGEPAL, 5%
b-mercaptoethanol). Samples containing equal quantity of protein,
as determined by Bradford’s method (Bio-Rad, Hercules, CA,
USA), were denatured in sample buffer (Invitrogen) for 10min at
701C and resolved on a 4–12% Bis–Tris acrylamide gel (Invitro-
gen) along with molecular size markers. Electrophoresis was
carried out at constant voltage (200V) at room temperature.
Proteins were electrophoretically transferred to Immobilon poly-
vinylidene difluoride membrane (Millipore, Bedford, MA, USA) at
a constant voltage (100V) for 1h at 41C. Following the transfer, the
blot was stained with Ponceau Red-S to check the efficiency of
transfer, blocked with 10% non-fat dry milk, incubated with rabbit
primary antibodies against CPO (1:5000), p27 (Santa Cruz
Biotech, Santa Cruz, CA, USA) (1:1000), and E-cadherin (Santa
Cruz) (1:1000) followed by peroxidase-conjugated goat anti-rabbit
IgG (1:20,000; Jackson ImmunoResearch, West Grove, PA, USA),
and developed using enhanced chemiluminescence reagents (ECL
kit, Amersham Biosciences, Piscataway, NJ, USA) as described
(Passi et al, 2004).
Statistics
Two-sample t-tests were used to compare the amount of PpIX
accumulation and cytotoxicity between treated and untreated
controls (Figures 3, 4, 6, and 7). In addition, analyses of variance
(ANOVA) were performed to determine whether there was an
additive vs synergistic effect in Figure 4 by testing the interaction
term between MTX and ALA-PDT. A P-value of 0.05 or less was
considered statistically significant.
RESULTS
Methotrexate stimulates accumulation of intracellular
PpIX while promoting growth arrest, differentiation, and
apoptosis in LNCaP cells.
We had previously described a strong increase in PpIX accumu-
lation in epithelial keratinocytes that were differentiating in
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response to androgens (Ortel et al, 2002). To establish whether
such a correlation might exist if MTX were used as the
prodifferentiating agent, LNCaP cells were pretreated for 72h with
a cytostatic dose of MTX (1mgl
 1; see details below), then
exposed to ALA for the last 4h, and analysed for the amount of
PpIX synthesised within the cells. Qualitatively, MTX pretreatment
led to a significantly higher PpIX accumulation as compared
to non-pretreated controls (Figure 1). The same MTX treatment
led to growth arrest, as measured by a complete block on
cell proliferation (Figure 2A), and by the accumulation of the cell-
cycle inhibitor, p27/kip-1 (Figure 2B, upper), whose upregulation
correlates with growth arrest in LNCaP cells (Campbell et al, 1997).
Methotrexate also promoted cellular differentiation, as measured
by a significant rise in E-cadherin (Figure 2B, middle), a marker
of differentiation in the LNCaP cells (Campbell et al, 1997).
The induction of the differentiation marker was MTX dose-
dependent (Figure 2B, lower). At the 1mgl
 1 concentration,
MTX also triggered classical apoptosis, as measured by fluores-
cent-activated cell analysis with annexin V (Figure 2C). The
net effect of growth arrest and apoptosis was to reduce the
total number of cells in MTX-treated dishes to B25% of
the number in untreated control dishes at the end of the 72h
period (Figure 2A).
The mechanism by which MTX enhances accumulation of
PpIX involves the haeme synthesis pathway
We examined the phenomenon of MTX-mediated enhancement of
intracellular PpIX levels in LNCaP cells in detail. Enhancement
occurred consistently in eight out of eight experiments, with some
variability in magnitude between experiments; typically, a three-
fold increase in PpIX was observed in MTX-conditioned vs
nonconditioned cells (Figure 3A). The PpIX-elevating effect of
MTX was only slightly less robust than that of a positive control,
the androgen R1881 shown previously to induce PpIX levels in this
cell line (Ortel et al, 2002).
To study the effect of ALA concentration upon PpIX accumula-
tion, ALA dose-ranging experiments in the presence or absence of
MTX were performed. Protoporphyrin IX content was seen to rise
monotonically with increasing ALA concentration (Figure 3B), and
the slope of the curve was markedly higher in the presence of MTX
(open circles) than in its absence (closed circles). Protoporphyrin
IX elevation was appreciated even at the lowest ALA concentra-
tions tested (see Figure 3B, inset).
To rule out the possibility that PpIX accumulation in MTX-
preconditioned cells might be owing to increased membrane
transport of ALA precursors, we used ALA and two of its alkyl
esters, 5-methyl-ALA (m-ALA) and 5-hexyl-ALA (h-ALA), in
comparative experiments (Figure 3C). Our approach was based on
reports that show distinct membrane transport mechanisms for
ALA and m-ALA. 5-Aminolaevulinic acid enters cells via
membrane pores that also transport b-amino acids and GABA,
whereas m-ALA uses a different route (Rud et al, 2000; Gederaas
et al, 2001). Although details of the transport mechanism for
hexyl-ALA uptake are not known, it also appears to be distinct
from b-amino-acid transport (Rud et al, 2000). To examine
whether MTX might preferentially alter PpIX accumulation
depending upon whether the prodrug was in the form of free
ALA or one of its esters, LNCaP cells were pretreated with MTX or
media (control) for 72h, and then exposed to ALA, m-ALA, or h-
ALA for 4h. Cellular production of PpIX was assessed by
quantitative spectrofluorometry (Figure 3C). Because the hexyl
ester of ALA is significantly more permeable than ALA itself, it was
necessary to use 300 times less h-ALA (1mM) than ALA (0.3mM)t o
achieve a comparable baseline level of PpIX (Figure 3C, fifth vs
first bar). However, under conditions in which ALA and its esters
give similar PpIX levels at baseline, the addition of MTX caused a
similar degree of PpIX accumulation (three- to five-fold),
regardless of which form of ALA was used. Because it seems
highly unlikely that MTX could affect three different membrane
ALA-transporting mechanisms to exactly the same extent, the
PpIX-elevating action of MTX does not occur primarily through an
effect upon precursor uptake.
– MTX, – ALA – MTX, + ALA + MTX,+ ALA
50   m
Figure 1 Methotrexate pretreatment stimulates the accumulation of PpIX in LNCaP cells. LNCaP cells, seeded in 35mm dishes 1 day previously, were
incubated in culture medium containing MTX (1mgl
 1; þMTX), or in medium without additives ( MTX). After 72h, ALA was added to some of the
dishes (0.3mM, þALA; middle and right panels) and the cells were incubated for an additional 4h. Protoporphyrin IX-specific fluorescence was analysed by
fluorescence microscopy (see Materials and Methods). Upper panels: phase-contrast images. Lower panels: PpIX-fluorescent images. Scale bar, 50mm.
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photodynamic treatment
We next tested whether the elevated intracellular levels of PpIX,
observed in MTX-preconditioned cells, can have functional
consequences in terms of cell survival after exposure to visible
light. LNCaP cells were pretreated with MTX for 72h, exposed to
ALA for 4h, and then irradiated with 512nm light and analysed for
cytotoxicity using two different assays, MTT dye conversion
(Figure 4A and B), and colony formation (Figure 4C and D). 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide con-
version at 24h is a short-term cytotoxicity assay; MTT serves as an
indicator of intact cellular metabolism. In a typical experiment
(Figure 4A), MTX caused an initial B75% decrease in viability as
compared to nonconditioned cells; the subsequent administration
of light caused an additional 41log of cell kill, considerably more
than in nonconditioned cells. Because the absolute magnitude of
viability data often varies between experiments, we expressed the
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Figure 2 Effect of MTX upon LNCaP growth, differentiation, and
apoptosis. (A) Inhibition of cell growth by MTX. LNCaP cells were
incubated for 72h in medium containing 1mgl
 1 MTX, or solvent alone
(control). Proliferation is indicated by a 350% net increase in cell number at
72h vs no increase with MTX. Mean of two experiments carried out in
duplicate, 7s.d. (B) Western blots of LNCaP cells incubated in the
presence of MTX, and analysed with specific antisera to growth arrest
marker (p27/kip-1; upper panel) and a differentiation marker (E-cadherin;
lower panels). The upper panels show a time course of induction at a fixed
MTX concentration (1mgl
 1); the lower panel shows a dose–response
study with a fixed incubation time of 72h. The E-cadherin doublet at 124
and 135kDa (lower panel; Bis–Tris gel) was not well resolved on the
smaller, Tris-glycine gel (middle panel). (C) Analysis of apoptosis in LNCaP
cells after incubation with MTX. Cells were incubated for 72h in the
presence or absence of MTX, as indicated. Adherent and nonadherent cells
were pooled and analysed by FACS analysis. The sub-G1 fraction
(apoptotic cells, closed bars) and the G1þSþG2/M fractions (living cells,
open bars) were expressed as a percentage of total cell number. Bars show
mean of six experiments7s.d.
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Figure 3 Effect of MTX upon ALA-mediated PpIX accumulation. (A)
Pretreatment of LNCaP cells with MTX enhances ALA-induced PpIX
accumulation. Cells were cultured in the presence of MTX (1mgl
 1; grey
bar) for 72h, then ALA (0.3mM) was added for 4h, and cells harvested for
measurements of intracellular PpIX. For a positive control, some dishes
were incubated with an androgen, R1881 (0.1mM; black bar) for 72h.
Protoporphyrin IX concentrations, calculated from a standard curve, were
expressed on a per cell basis. Bars are the mean of eight experi-
ments7s.e.m. (*), two-sample t-test, Po0.001. (B) Methotrexate
enhances PpIX accumulation in LNCaP cells over a range of ALA
concentrations. Cells were pretreated with MTX (open circles) or medium
alone (solid circles) for 72h, then incubated for 4h in different ALA
concentrations before harvest. This experiment shows mean7range of
duplicate determinations at each point. Two additional experiments gave
qualitatively similar results (not shown). (Inset) Enlargement of the graph at
0.3mM ALA; note that MTX enhancement of PpIX occurred even at the
lowest ALA dose. (Asterisks) Two-sample t-test, comparing MTX to
control at the same dose of ALA; (*) Po0.05; (**) Po0.001. (C) Effect of
MTX upon accumulation of PpIX derived from different ALA esters. Cells
were incubated for 72h in the absence or presence of MTX, and then for
4h in the presence of either ALA (0.3mM), methyl-ALA (0.5mM), or hexyl-
ALA (1mM) before harvest and PpIX measurement. Bars are the
mean7s.e.m. for three experiments, each performed in duplicate.
Numbers above each bracket indicate relative increase (-fold) in PpIX
owing to MTX. Note the similar -fold increase with all three analogues.
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sdata as per cent survival (relative to nonirradiated controls) in
order to allow the normalisation and pooling of multiple
experiments. These aggregate results demonstrated that the
enhancement of cytotoxicity in the MTX-preconditioned group
was statistically significant (Figure 4B). To assess long-term
survival, clonogenic growth of the LNCaP cells at B2 weeks after
irradiation was plotted against increasing doses of light
(Figure 4C). Again, MTX significantly enhanced cell killing in
the photodynamic regimen, and when the results of multiple
experiments were pooled and compared, the improvement with
MTX was highly significant (Figure 4D).
To begin to determine whether MTX and ALA-PDT were
working independently to promote cell killing, we subjected the
data to an ANOVA. In our experiments, the combination of MTX
pretreatment and ALA-PDT were synergistic for cell killing only at
the lowest dose of light (4Jcm
 2, Po0.001), but in general the
lethal effects of MTX and ALA-PDT were additive.
The MTX effect upon ALA-mediated cell killing is
order-dependent
Although we hypothesised that enhanced cytotoxicity with MTX
occurs because PpIX production is increased in the MTX-
preconditioned cells, other possible mechanisms warranted con-
sideration. For example, because MTX inhibits cell proliferation,
lower cell densities in the cultures at the time of PDT could
hypothetically lead to differences in cellular cytotoxic responses.
Therefore, we were careful to eliminate cell density as a variable by
adjusting the number of cells plated so as to yield an equivalent
cell density at the time of irradiation (see Materials and Methods).
An equally important possibility was that MTX might affect
cell behaviour after photodynamic treatment, for example, by
accelerating cell death pathways. To test this possibility, we
reversed the order of MTX and ALA-plus-light treatments
(Figure 5). Cells were subjected to ALA and light exposure first,
followed by a 72h exposure to MTX. Under these conditions, no
significant differences in long-term cell survival between MTX- vs
vehicle-treated cells were observed (Figure 5). These data indicate
that the presence of MTX does not appreciably alter the
mechanisms of cell lethality, once initiated by ALA-PDT.
Methotrexate at noncytotoxic concentrations induces
PpIX levels
Whereas the majority of the preceding data were obtained with a
relatively high concentration of MTX (1mgl
 1¼2.2mM), chosen to
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Figure 4 Pretreatment of LNCaP cells with MTX enhances cytotoxicity after the addition of ALA and light. Survival was measured by MTT dye
conversion (A and B) or by colony formation (C and D), and presented in two ways. Raw data from a single, typical experiment are shown (A and C),
followed by the per cent survival (relative to unirradiated controls), pooled from multiple experiments (B and D). In all cases, cells were preconditioned for
72h with MTX (1mgl
 1; triangles) or medium alone (circles), then incubated with ALA (0.3mM) for 4h and irradiated with light. (A) MTT dye assay at 24h,
single experiment. (B) MTT dye assay, pooled experiments. Mean7s.e.m. of four experiments. (*), Po0.05. (C) Colony formation assay at 13-day, single
experiment. (D) Colony formation assay at 13-day, pooled experiments. Mean7s.e.m. of four experiments. (**), Po0.0005. See Materials and Methods and
Results for further details.
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sapproximate the therapeutic levels typically sought in the clinic,
MTX at that concentration has antiproliferative and cytotoxic
effects in addition to the prodifferentiating effects of particular
interest here. To ask whether lower MTX doses might promote
accumulation of PpIX, LNCaP cells were exposed to MTX
concentrations over a wide range (a 1000-fold, 2.2mM–2.2nM)
and PpIX levels were assessed by semiquantitative confocal
microscopy (Figure 6A–D). The results demonstrated an MTX-
dependent increase in PpIX levels, seen with MTX concentrations
as low as 2.2nM (Figure 6E). From this, we conclude that
low, nontoxic concentrations of MTX can promote significant
accumulation of PpIX.
Methotrexate enhances PpIX levels via an upregulation of
CPO
To test for changes in the enzymes most likely to be involved in an
accumulation of PpIX in the haeme synthesis pathway, we
considered several potentially rate-limiting enzymes both proximal
and distal to PpIX (for a schematic of this pathway, see Figure 8).
Given prior evidence that CPO was involved in raising PpIX levels
in differentiating epithelial cells (Ortel et al, 1998), we were
especially interested in whether CPO gene expression was altered
by MTX. To test for changes in mRNA expression, LNCaP cells
were treated with MTX or with media alone, and RT–PCR was
performed. Using gene-specific primers at the reverse transcrip-
tion step, followed by a CPO-specific primer pair (see Materials
and Methods), a significant and reproducible 2.5-fold increase
in CPO mRNA level was observed (Figure 7A and B). Reverse
transcription–polymerase chain reaction analyses with gene-
specific priming for PPO, ferrochelatase, and PBGD demonstrated
no changes in mRNA expression (data not shown), indicating no
major effects upon gene expression for those enzymes.
To demonstrate the effect of MTX upon CPO at the protein level,
we generated a rabbit antiserum to a defined epitope of the CPO
enzyme (see Materials and Methods). The antiserum detected
a 38kDa complex on Western blots of lysates from cos-7 cells
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Figure 5 Photodynamic therapy is not enhanced if MTX is administered
after ALA and light. Cells were first subjected to ALA-PDT treatment (4h
of ALA 0.3mM, followed by exposure to graduated light doses) and plated
for colony formation assay. Subsequently, one set of plates was exposed to
MTX for 72h, the other to medium only. Colonies were counted at 13
days. (A) Colony formation assay, single experiment. (B) Colony formation
assay, pooled experiments. Mean of four experiments7s.e.m.
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Figure 6 Very low concentrations of MTX can enhance PpIX in LNCaP
cells. At time zero, LNCaP cells (3 10
5cellsdish
 1) were plated on glass
cover slips as described in Materials and Methods, and at 24h, switched to
medium containing variable quantities of MTX (0.001–1.0mgl
 1). At 72h,
new medium with 1mM ALA was added and cells were incubated for 4h
before visualisation of PpIX-specific fluorescence by confocal microscopy.
(A–D) Representative images (shown here in grey scale) of PpIX-specific
fluorescence in LNCaP cells at the MTX concentrations indicated. (E)
Semiquantitative analysis of the relative number of cells that were PpIX-
positive (% of total cells), performed as described in Materials and Methods.
Bars are the mean7s.d. of three digital images per transfection. (*)
Po0.001; (**) Po0.0005. The experiment was performed twice with
similar results.
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stransfected with a plasmid vector expressing full-length murine
CPO (Figure 7C, left). The largest band at 38kDa corresponds to
the predicted size of mature CPO (Ortel et al, 1998), whereas the
two smaller forms may represent proteolytic processing or
translation occurring from internal ribosome-initiation sites.
Time-course experiments, from LNCaP cells harvested at different
times in MTX-containing media (Figure 7C, right), revealed
significant changes in a band with the same relative migration
(38kDa) as authentic CPO in the cos-7 lysates. Quantitation of
CPO expression from several experiments showed a reproducible
increase in this band, detectable by 12h and rising three-fold by
48h (Figure 7D). We conclude that MTX causes a significant
accumulation of CPO at both the mRNA and protein levels.
As another way to investigate the link between induced CPO
expression and enhanced PpIX levels, a cDNA plasmid vector
expressing murine CPO was transiently transfected into LNCaP
cells and PpIX levels were observed by confocal microscopy
(Figure 7E and F). Compared to an empty-vector control, the
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Figure 7 Demonstration that MTX treatment leads to increased levels of CPO. (A) Methotrexate treatment of LNCaP cells causes accumulation of CPO
mRNA. Cells were exposed for various times to MTX (1mgl
 1), or remained untreated (0h). Cells were lysed, cDNA prepared, and RT–PCR performed
using a CPO gene-specific primer set, as described in Materials and Methods. The resulting PCR product was confirmed by DNA sequencing and by size-
similarity to a known plasmid cDNA (not shown). The ethidium-stained, CPO-specific bands are shown here inverted (dark bands). G3PDH, invariant
control. (B) Semiquantitative analysis of CPO mRNA. Agarose gels were digitally photographed, and the integrated density of each band measured using
NIH Image software. Induction (relative to untreated controls) was calculated after background subtraction and normalisation to the G3PDH bands.
Mean7range of two experiments. (C, left side) The anti-CPO epitope antibody recognises full-length CPO protein. Lysates from cos-7 cells were
transfected with a plasmid vector (pCPO) expressing CPO inserted in either the sense (S) or antisense (AS) orientation, and analysed by Western blot using
the antiserum to CPO. Arrow: CPO-specific signal; NS, nonspecific. (C, right side) CPO is expressed in LNCaP cells and increases with MTX treatment.
Equal amounts of protein from lysed cells were separated on acrylamide gels, and immunoblotted with antibodies to CPO, prostate-specific antigen, or actin.
The 38kDa CPO protein is indicated. (D) Semiquantitative analysis of CPO protein. Western blots from experiments examining long and short times of
exposure to MTX were scanned densitometrically, and the data combined. Error bars: range of duplicate experiments. (E) Fluorescence images, captured
from LNCaP cells that were either not transfected (No DNA), transfected with an empty pcDNA3.1 vector (Vector only), or transfected with different
amounts of a plasmid vector overexpressing CPO, followed by incubation with ALA and analysis of the PpIX-specific signal by confocal microscopy. The
PpIX-specific signal is shown in grey scale. (F) Semiquantitative analysis of relative PpIX-positive cells (% of total cells) was performed as described in
Materials and Methods. Bars represent the mean7s.d. of three images from each of two dishes; Asterisks, Po0.0005 relative to the vector-only control.
Methotrexate and photodynamic therapy of LNCaP cells
AK Sinha et al
492
British Journal of Cancer (2006) 95(4), 485–495 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sCPO-containing vector caused a dose-dependent increase in PpIX
signal within the cells (Figure 7E). This increase was statistically
significant (Figure 7F).
DISCUSSION
Owing to the complex nature of cancer development and
progression, it is becoming increasingly clear that no single
therapeutic modality is likely to be curative. It is now generally
accepted that newer molecular mechanism-based therapeutics,
particularly those in combination regimens, are more likely to
eradicate malignant disease. In this study, we present a novel
combination treatment that utilises cellular differentiation and
photodynamic destruction of prostate cancer cells. When adminis-
tered in the proper order, each modality enhances the other, as
evidenced by an improved overall outcome in terms of cell killing.
Our demonstration of a new combination therapy for ALA-PDT
is important because it captures the advantages of PDT-based
localised treatment, while using cellular physiology to produce an
overall enhanced outcome. 5-Aminolaevulinic acid-PDT provides
the targeting specificity. 5-Aminolaevulinic acid, an inert pharma-
cological precursor, remains inactive until it is converted into a
photosensitising agent (PpIX) within the target tissue, thereby
confining phototoxic chemical events to the target cells and
reducing toxic side effects (Kennedy et al, 1990; Iinuma et al,
1994). However, because tumour eradication with ALA-PDT is not
always obtained, a new combination that enhances ALA-PDT
would be very useful. Four parameters are necessary for effective
PDT: the photosensitising agent, light, oxygen, and cellular physio-
logy. Although many laboratories are attempting to optimise the
first three (physical) parameters, we are particularly interested in
the cell-physiologic aspects. If higher levels of PpIX could be
obtained by proper manipulation of the cellular metabolic state,
then photodynamic efficacy could be improved. Methotrexate was
chosen as an attractive candidate agent because MTX is already
used widely in the clinical arena, has relatively low toxicity, and
exerts its own antitumour effects by inhibiting proliferation,
promoting apoptosis, and promoting terminal differentiation
(Hatse et al, 1999). The ability to promote differentiation, in
particular, suggested to us the idea of using MTX in combination
with ALA-PDT. Two other agents (androgens and vitamin D) are
known to promote cellular differentiation and at the same time to
enhance PpIX accumulation in LNCaP cells (Ortel et al, 2002). We
decided to test MTX for a similar capability. The concept is to
administer MTX in a transient way, preparing the cells for PDT by
promoting accumulation of the PpIX photosensitiser.
Our results show that this combined approach is indeed feasible.
Preconditioning LNCaP cells with MTX sensitises them to subse-
quent ALA-PDT, and increases cell killing. An important finding
was the fact that for MTX to affect cell lethality, it must be
administered before the ALA and light, and not in the reverse
order (Figure 5). This suggests that MTX prepares the cell for
death by enhancing accumulation of PpIX rather than by affecting
postirradiation events. Methotrexate-related increases in PpIX
accumulation are substantial (always over three-fold) and nearly as
robust as PpIX induction seen with androgenic hormones. The
PpIX-elevating effects of MTX occurs across a range of ALA
concentrations (Figure 3B), suggesting that despite variations in
ALA concentration within tissue, sufficient PpIX might accumulate
in various parts of a tumour to provide effective photosensitisa-
tion. Further, we found that PpIX elevation occurs over a wide
range of MTX concentrations. Very low concentrations of MTX,
100- to 1000-fold lower than the high-dose regimen of 1.0mgl
 1
used in the cell-survival portion of our study, can significantly
boost the accumulation PpIX in LNCaP cells (Figure 6). This
implies that even when MTX penetration into a tumour is
relatively poor, a significant enhancement of PpIX may still be
possible. The cell-survival studies performed here at MTX
1.0mgl
 1 showed a combined effect of MTX and ALA-PDT that
was only additive, but this may relate to the very real possibility
that the dose of MTX that we were using was (in retrospect) too
high to detect a synergistic effect. Further studies are planned to
ask whether very low-dose MTX combined with ALA-PDT can
produce synergistic killing, as well as to validate whether the
phenomenon can be reproduced in three-dimensional tissue
culture and animal models.
To investigate the mechanisms of increased PpIX accumulation,
we first asked whether MTX might be affecting cellular uptake of
5-ALA. Using different ALA esters as the exogenous source for the
production of PpIX (Figure 3C), we found that MTX exerted a
similar PpIX-elevating effect, regardless of which ester-specific
transport pathway was employed. Although not completely ruling
out an effect of MTX upon ALA uptake, the data led us to search
for other possible effects of MTX, such as altered PpIX synthesis
and/or degradation. For this, we looked at the expression of
enzymes in the haeme-synthetic pathway (see cartoon in Figure 8).
No changes in mRNA expression were seen for PBGD, PPO, or
ferrochelatase. However, a significant three-fold increase in the
level of CPO was found to occur. To be sure of these results, we
devoted considerable time toward developing an RT–PCR assay
that could reliably detect small changes in CPO message levels.
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1    ALAS   aminolevulinic acid synthase
2    ALAD   ALA dehydratase
3    PBGD   porphobilinogen deaminase
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5   UDC   uropophyrinogen decarboxylase
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Figure 8 Schematic of porphyrin-synthetic pathway to illustrate potential
control points for increased PpIX accumulation. Enzymes, with names
abbreviated and relative locations in the pathway shown in boxes, are
numbered beginning with the initial condensation of glycine and succinyl-
CoA. Substrates/products are shown in bold font. The intracellular location
of enzymes, relative to the mitochondria and the cytoplasm, is indicated.
See Bickers et al (1999) for a fully detailed version.
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sPilot experiments with conventional primers for reverse transcrip-
tion (oligo-dT, or random hexamers) failed to show any changes in
CPO expression, despite amplification in the linear range. Potential
problems can occur with the oligo-dT approach when reverse
transcription starting at the 30 end of the RNA leads to under-
representation of the 50 ends of rare transcripts, and random
hexamer primers may also amplify an incorrect proportion of
transcripts because of failure to produce full-length cDNAs. To
resolve these uncertainties, we devised CPO gene-specific primers
to direct first-strand cDNA synthesis. Under these conditions,
reproducible increases in CPO mRNA from MTX-treated cells were
demonstrated (Figure 7B). To show a corresponding increase in
CPO protein, it was necessary to develop our own epitope-specific
antiserum to CPO. After verifying its specificity against a
recombinant CPO protein expressed in cos-7 cells, we used the
antiserum to show that LNCaP cells produce CPO at higher
amounts in cells preconditioned with MTX (Figure 7C and D).
Relative increases in CPO mRNA and protein were modest,
Bthree-fold; yet, they can fully account for the three-fold increase
in PpIX levels observed in our study. Transfection studies, in
which the CPO enzyme was forcibly expressed in the LNCaP cells,
confirmed that an elevation in PpIX levels can result from
increased expression of CPO (Figure 7E and F).
The idea of a link between terminal differentiation and the CPO
enzyme, in the regulation of intracellular porphyrin levels, has
some precedence in the literature. In blood, where regulation of
porphyrins has been intensively studied, a relationship between
CPO levels and erythroid cell differentiation was convincingly
established. For example, murine erythroleukaemia MEL cells
induced to differentiate by dimethylsulphoxide (DMSO), showed a
large induction in mRNA for CPO within 10h (Kohno et al, 1993).
Likewise, human erythroleukaemia K562 cells undergoing differen-
tiation in the presence of TGF-b, also displayed increased CPO
expression (Taketani et al, 2001). In erythroid cells, differentia-
tion-inducing agents induced several of the haeme-synthetic
enzymes simultaneously (Taketani et al, 1995), but even under
such circumstances, CPO may be rate-limiting and therefore
important in the regulation of haeme and PpIX production
(Conder et al, 1991). Our own demonstrations of CPO upregula-
tion in differentiating keratinocytes (Ortel et al, 1998) and LNCaP
cells (Ortel et al, 2002) were among the first to demonstrate such a
link in nonhaematopoietic cells. How MTX causes an increase in
CPO expression in these situations remains an open question, but
possibilities for transcriptional regulation of the CPO promoter are
intriguing. For example, MTX regulates expression of three
transcription factors, Cdx2, GATA-4, and HNF-1a, that are
important for epithelium differentiation in a mouse model of
induced intestinal damage (de Koning et al, 2006). Putative
binding sites for the above-mentioned transcription factors on the
murine CPO promoter might account for increased CPO expres-
sion following MTX treatment of LNCaP cells (Takahashi et al,
1998; Maytin et al, 2006).
The notion that MTX-induced effects upon PpIX levels in the
LNCaP cells might be linked to induction of a differentiated
phenotype per se remains open to conjecture. We have not yet
exhaustively investigated the relative effects of very low-dose MTX
upon differentiation, apoptosis, and growth arrest of LNCaP
(although apoptosis appears to be an insignificant fraction). In
human choriocarcinoma (BeWo) cells, a well-established model of
MTX-induced differentiation (Friedman and Skehan, 1979);
treatment with MTX induces cytodifferentiation at concentrations
between 10
 8 and 10
 7 M (Burres and Cass, 1987). Similarly in
cultured human keratinocytes, MTX in the 10
 8 to 10
 7 M range
was reported to induce only 1% apoptotic cells (Heenen et al,
1998) while inducing significant numbers of differentiated
(involucrin-positive) cells (Schwartz et al, 1992) in the cultures.
In LNCaP cells, at this point, we can only say that MTX (at low
nontoxic concentrations) clearly promotes the accumulation of
PpIX, and that further studies are underway.
The current study broadens the number of situations in which
epithelial-type cancer cells can be manipulated to produce higher
levels of PpIX endogenously, in this case using an agent (MTX)
commonly used in the clinic for cancer chemotherapy. Future
studies will be needed to establish whether MTX can be effectively
combined with ALA-PDT in the clinical setting.
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